- Home
- PTY vs PTGX Comparison
PTY vs PTGX Comparison
Compare PTY & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTY
- PTGX
- Stock Information
- Founded
- PTY 2002
- PTGX 2006
- Country
- PTY United States
- PTGX United States
- Employees
- PTY N/A
- PTGX N/A
- Industry
- PTY Investment Managers
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- PTY Finance
- PTGX Health Care
- Exchange
- PTY Nasdaq
- PTGX Nasdaq
- Market Cap
- PTY 2.5B
- PTGX 2.9B
- IPO Year
- PTY N/A
- PTGX 2016
- Fundamental
- Price
- PTY $13.79
- PTGX $50.15
- Analyst Decision
- PTY
- PTGX Strong Buy
- Analyst Count
- PTY 0
- PTGX 8
- Target Price
- PTY N/A
- PTGX $66.50
- AVG Volume (30 Days)
- PTY 550.4K
- PTGX 820.5K
- Earning Date
- PTY 01-01-0001
- PTGX 05-06-2025
- Dividend Yield
- PTY 9.65%
- PTGX N/A
- EPS Growth
- PTY N/A
- PTGX N/A
- EPS
- PTY N/A
- PTGX 0.86
- Revenue
- PTY N/A
- PTGX $207,801,000.00
- Revenue This Year
- PTY N/A
- PTGX N/A
- Revenue Next Year
- PTY N/A
- PTGX $50.30
- P/E Ratio
- PTY N/A
- PTGX $55.04
- Revenue Growth
- PTY N/A
- PTGX N/A
- 52 Week Low
- PTY $11.92
- PTGX $28.36
- 52 Week High
- PTY $14.88
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- PTY 53.98
- PTGX 66.59
- Support Level
- PTY $13.58
- PTGX $45.43
- Resistance Level
- PTY $13.72
- PTGX $46.80
- Average True Range (ATR)
- PTY 0.11
- PTGX 1.59
- MACD
- PTY -0.00
- PTGX 0.51
- Stochastic Oscillator
- PTY 56.76
- PTGX 98.93
About PTY Pimco Corporate & Income Opportunity Fund
PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on a public or private basis.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.